Zentalis

Zentalis : Discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. Multiple mono and combo trials are ongoing/planned across the pipeline.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
Oncology
Listing
Public, USA
Market Cap
1B +
Website:
Profiles:
Address:
1359 Broadway
New York, NY 10018
United States

Company Participants at Solebury 1x1 Management Access Event 2023

  • Kim Blackwell, Dr., Chief Executive Officer

Upcoming Company Event Participation

Lead Programs

ZN-c5: Oral SERD

oral selective estrogen receptor degrader (SERD)

Indication Phase
Breast Cancer 1/2

ZN-c3: WEE1

oral inhibitor of WEE1

Indication Phase
Solid Tumors 1/2

ZN-d5: BCL-2

oral selective inhibitor of B-cell lymphoma 2 (BCL-2)

Indication Phase
Hematologic Malignancies IND

ZN-e4: EGFR

oral, small molecule inhibitor of mutant epidermal growth factor receptor (EGFR)

Indication Phase
NSCLC 1/2

Top 10 Holders of Zentalis Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Matrix Capital Management Co. LP 16.14 9,199,973 199.00 13F 9/30/22
Fidelity Management & Research Co. LLC 11.30 6,439,878 139.29 13F 9/30/22
Avidity Partners Management LP 7.41 4,223,100 91.35 13F 9/30/22
Vanguard Group, Inc. (Subfiler) 7.00 3,987,153 86.24 13F 9/30/22
The Vanguard Group, Inc. 7.03 3,186,986 68.93 Stakes 12/31/21
Wellington Management Co. LLP 5.48 3,122,364 67.54 13F 9/30/22
State Street Corp. 5.00 2,850,174 61.65 13F 9/30/22
Tybourne Capital Management (HK) Ltd. 4.04 2,301,771 49.79 13F 9/30/22
T. Rowe Price Associates, Inc. (Investment Management) 3.89 2,217,740 47.97 13F 9/30/22
T. Rowe Price Investment Management, Inc. 3.88 2,208,669 47.77 13F 9/30/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.